Skip to main content

Table 1 The relationship between m6A enzyme mRNA expression and clinicopathological parameters with breast cancer. (Data from bc-GenExMiner v4.0)

From: Changes of N6-methyladenosine modulators promote breast cancer progression

Parameter

Status

METTL3

METTL14

WTAP

KIAA1429

FTO

ALKBH5

No.

mRNA

No.

mRNA

No.

mRNA

No.

mRNA

No.

mRNA

No.

mRNA

Age

≤51

1302

1

810

1

1303

1

548

1

1192

1

766

1

> 51

2051

Nc

1673

Nc

2051

Nc

959

Nc

1896

Nc

1546

Up**

ER (IHC)

1488

1

949

1

1376

1

453

1

1383

1

892

1

+

3810

Up***

2374

Up***

3588

Down***

1282

Up***

3650

Up***

2261

Up**

PR (IHC)

871

1

560

1

729

1

270

1

871

1

560

1

+

1365

Up***

935

Up***

1175

Down***

504

Up***

1365

Up***

935

Up*

HER2 (IHC)

1286

1

548

1

1286

1

405

1

1286

1

548

1

+

175

Nc

134

Nc

175

Nc

122

Down*

175

Down**

134

Nc

TNBC

+

356

1

179

1

356

1

116

1

356

1

179

1

3968

Up***

2494

Up***

3726

Down***

1366

Up**

3808

Up*

2381

Nc

Nodal

2375

1

1251

1

2376

1

698

1

2230

1

1251

1

+

1432

Nc

1064

Up*

1432

Nc

571

Nc

1312

Nc

1064

Nc

  1. Nc No, change; Up upregulation, Down downregualtion, ER estrogen receptor, PR progesterone-receptor, HER2 human epidermal growth factor receptor 2, TNBC triple-negative breast cancer. *p < 0.05, **p < 0.01, ***p < 0.001